Skip to main content

Search Videos and More

Showing 13 - 24 of 69 results

Previous| 1 | 2 | 3 ...6 |Next

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world?

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world?

Given the results of ODYSSEY, FOURIER, and others, as a lipid/atherosclerosis specialist what is your take home about what the appetite should be for using PCSK9 inhibitors to lower LDL-C levels beyond ESC and AHA recommended thresholds of 70 mg/dL?

Given the results of ODYSSEY, FOURIER, and others, as a lipid/atherosclerosis specialist what is your take home about what the appetite should be for using PCSK9 inhibitors to lower LDL-C levels beyond ESC and AHA recommended thresholds of 70 mg/dL?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the lipid and atherosclerosis disease specialist interpret the ESC and AHA Guideline threshold of 70 mg/dL LDL-C level and determine whether even lower levels are even better to mitigate residual CV risk?

How should the lipid and atherosclerosis disease specialist interpret the ESC and AHA Guideline threshold of 70 mg/dL LDL-C level and determine whether even lower levels are even better to mitigate residual CV risk?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction?

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Which patients, in your view, are not candidates for PCSK9 inhibition?

Which patients, in your view, are not candidates for PCSK9 inhibition?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

Showing 13 - 24 of 69 results

Previous| 1 | 2 | 3 ...6 |Next